Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 6th Conference on Retroviruses and Opportunistic Infections
Abstract No. 401: Tailoring Drug Treatments with the Use of Hydroxyurea

February 2, 1999

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

This two-part study, conducted by Franco Lori, et al., first analyzed the efficacy of beginning treatment soon after HIV infection occurs, a period known as primary infection. In the primary infection study ten patients with a very high average baseline viral load of 551,217 copies were treated with hydroxyurea (HU), ddI and the protease inhibitor indinavir. Patients began treatment within 1.7 months (mean) after infection. All patients' viral loads reached undetectable levels (under 50 copies) within 4 to 16 weeks, and after a mean treatment period of 46 weeks their T-cells counts had increased an average of 154 cells. An special analysis of the T-cells found them to be anti-HIV-specific.

In the parallel study, 12 patients with chronic HIV infection and a mean baseline viral load of 51,795 copies were treated with HU and ddI for a mean period of 122 weeks. Not all patients reached undetectable levels with this treatment: the mean viral load after 122 weeks 186, and the mean T0-cell increase was just 30 cells.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Abstract: Tailoring Drug Treatments with the Use of Hydroxyurea
Authored by: F. Lori, E. Rosenberg, H. Jessen, J. Lieberman, D. Finzi, E. Seminari, R. Maserati, R.F. Siliciano, B. Walker, and J. Lisziewicz

See Also
More on HIV Medications
More Research on Hydroxyurea
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement